{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:13:25Z","timestamp":1740143605203,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Immigrant Minority Health"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10903-022-01364-2","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T07:26:15Z","timestamp":1650093975000},"page":"1594-1598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening Practices for Latent Tuberculosis Infection in Clinical Trials Evaluating Treatments for Chronic Hepatitis B Virus Infection"],"prefix":"10.1007","volume":"24","author":[{"given":"Sandy","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit S.","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-2806","authenticated-orcid":false,"given":"Robert J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"1364_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07056-5","author":"J Chen","year":"2021","unstructured":"Chen J, Hubbard A, Bagley L, Shiau R, Wong RJ, Chitnis AS. Prevalence of latent tuberculosis infection among persons with chronic hepatitis B virus infection: a systematic review and meta-analysis. Dig Dis Sci. 2021. https:\/\/doi.org\/10.1007\/s10620-021-07056-5.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"1364_CR2","doi-asserted-by":"publisher","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","volume":"10","author":"R Miramontes","year":"2015","unstructured":"Miramontes R, Hill AN, Woodruff RSY, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011\u20132012. PLoS ONE. 2015;10(11):e0140881.","journal-title":"PLoS ONE"},{"issue":"10","key":"1364_CR3","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/jcm9103187","volume":"9","author":"A Alexopoulou","year":"2020","unstructured":"Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the treatment of chronic hepatitis B. J Clin Med. 2020;9(10):3187.","journal-title":"J Clin Med"},{"key":"1364_CR4","unstructured":"ClinicalTrials.gov. United States National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/home. Accessed 12 June 2021."},{"key":"1364_CR5","doi-asserted-by":"publisher","first-page":"e52668","DOI":"10.7554\/eLife.52668","volume":"9","author":"LB Tezera","year":"2020","unstructured":"Tezera LB, Bielecka MK, Ogongo P, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1. Elife. 2020;9:e52668. https:\/\/doi.org\/10.7554\/eLife.52668.","journal-title":"Elife"},{"key":"1364_CR6","doi-asserted-by":"publisher","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society\/Infectious Disease Society of America\/Centers for Disease Control and Prevention guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(20):e1\u2013e33. https:\/\/doi.org\/10.1093\/cid\/ciw694.","DOI":"10.1093\/cid\/ciw694"},{"key":"1364_CR7","unstructured":"World Health Organization. Use of high burden country lists for TB by WHO in the post-2015 era. https:\/\/www.who.int\/tb\/publications\/global_report\/high_tb_burdencountrylists2016-2020.pdf. Accessed 8 June 2021."},{"issue":"7","key":"1364_CR8","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","volume":"18","author":"G Walzl","year":"2018","unstructured":"Walzl G, McNerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018;18(7):e199\u2013210. https:\/\/doi.org\/10.1016\/S1473-3099(18)30111-7.","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"1364_CR9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098\u2013104.","journal-title":"N Engl J Med"}],"container-title":["Journal of Immigrant and Minority Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10903-022-01364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10903-022-01364-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10903-022-01364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T11:31:45Z","timestamp":1669375905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10903-022-01364-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s10903-022-01364-2","relation":{},"ISSN":["1557-1912","1557-1920"],"issn-type":[{"type":"print","value":"1557-1912"},{"type":"electronic","value":"1557-1920"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"31 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandy Le, Brian Martin, and Amit S. Chitnis are declares none. Robert J. Wong\u2014recipient of research grants to his academic institution from Gilead Sciences, and has served as a consultant on the advisory board and speaker\u2019s bureau for Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}